scholarly journals miR‑335 promotes ferroptosis by targeting ferritin heavy chain 1 in in vivo and in vitro models of Parkinson's disease

2021 ◽  
Vol 47 (4) ◽  
Author(s):  
Xinrong Li ◽  
Wenwen Si ◽  
Zhan Li ◽  
Ye Tian ◽  
Xuelei Liu ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Heavy Chain ◽  
In Vitro Models ◽  
Ferritin Heavy Chain

BAG1 is Neuroprotective in In Vivo and In Vitro Models of Parkinson’s Disease

2014 ◽  
Vol 55 (3) ◽  
pp. 587-595 ◽  
Author(s):  
Pawel Kermer ◽  
Anja Köhn ◽  
Marlena Schnieder ◽  
Paul Lingor ◽  
Mathias Bähr ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
In Vitro Models

Carvacrol Protects Against 6-Hydroxydopamine-Induced Neurotoxicity in In Vivo and In Vitro Models of Parkinson’s Disease

2019 ◽  
Vol 37 (1) ◽  
pp. 156-170 ◽  
Author(s):  
Mahboubeh Manouchehrabadi ◽  
Mona Farhadi ◽  
Zahra Azizi ◽  
Anahita Torkaman-Boutorabi
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
In Vitro Models ◽  
6 Hydroxydopamine

Implications of VIP and PACAP in Parkinson’s disease: what do we know so far?

2020 ◽  
Vol 27 ◽  
Author(s):  
Filipe Resende Oliveira de Souza ◽  
Fabiola Mara Ribeiro ◽  
Patricia Maria d' Almeida Lima
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Vasoactive Intestinal Peptide ◽  
In Vitro Models ◽  
Cytokines And Chemokines ◽  
Pituitary Adenylate Cyclase ◽  
Key Factor

Background: Parkinson’s disease is one of the most common neurodegenerative disorders and, although its etiology remains not yet fully understood, neuroinflammation has been pointed as a key factor for the progres-sion of the disease. Vasoactive intestinal peptide and pituitary adenilate-cyclase activating polypeptide are two neuropeptides that exhibit antiinflammatory and neuroprotective properties, modulating the production of cyto-kines and chemokines and the behaviour of immune cells. However, the role of chemokines and cytokines modu-lated by the endogenous receptors of the peptides vary according to the stage of the disease. Methods: Overview of the relationship between some cytokines and chemokines with vasoactive intestinal peptide, pituitary adenylate cyclase activating polypeptide and their endogenous receptors in the context of Parkinson’s disease neuroinflammation and oxidative stress, as well as the modulation of microglial cells by the peptides in this context. Results: The two peptides exhibit neuroprotective and antiinflammatory properties in models of Parkinson’s dis-ease, as they ameliorate cognitive functions, decrease the levels of neuroinflammation and promote dopaminergic neuronal survival. The peptides have been tested in a variety of in vivo and in vitro models of Parkinson’s disease, demonstrating potential for therapeutic application. Conclusion: More studies are needed to stablish the clinical use of vasoactive intestinal peptide and pituitary ade-nylate cyclase activating polypeptide as safe candidates for treating Parkinson’s disease, as the use of the peptides in different stages of the disease could produce different results concerning effectiveness.

scholarly journals Protective Effect of Compound Formula Rehmannia against Neurotoxicity and Apoptosis Induced by α-Syn in In Vivo and In Vitro Models of Parkinson’s Disease

2020 ◽  
Vol 2020 ◽  
pp. 1-11
Author(s):  
Long Teng ◽  
Minchun Yang ◽  
Xiaoqing Jin ◽  
Lu Qian ◽  
Weijia Yang ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Protective Effect ◽  
Cell Viability ◽  
Cell Apoptosis ◽  
In Vitro Models ◽  
Western Blot Assay ◽  
Rotation Numbers

The present study aimed to investigate the protective effect of compound formula Rehmannia (CFR) against the development of Parkinson’s disease (PD). After the in vivo and in vitro models of PD were established with overexpression α-syn induced, CFR was administrated into the PD model rats for 6 weeks or SK-N-SH cells with coincubation for 48 h. Apomorphine-induced rotation test, CCK8 assay, TUNEL assay, immunofluorescence staining, and western blot assay were performed to evaluate the behavioral changes, cell viability, cell apoptosis, α-syn, GSK-3β, P-GSK-3β (Ser9), P-GSK-3β (Tyr216), and β-catenin expression in PD rats or SK-N-SH cells. PD rat behavior results showed that the rotation numbers were significantly decreased in the CFR treatment group comparing with the AAV-α-syn PD model group. The cell viability suppressed by H2O2 and α-syn in SK-N-SH model cells was also significantly improved with CFR administration. Cell apoptosis and α-syn overexpression observed in PD rats and SK-N-SH cells were also inhibited by CFR treatment. Furthermore, the protein expression of α-syn, GSK-3β, P-GSK-3β (Ser9), P-GSK-3β (Tyr216), and β-catenin in in vivo and in vitro was also significantly regulated by CFR. The present study suggested that CFR may be considered as a potential neuroprotective agent against PD, and this application will require further investigation.

The Expression and Release of Hsp60 in 6-OHDA Induced In Vivo and In Vitro Models of Parkinson’s Disease

2013 ◽  
Vol 38 (10) ◽  
pp. 2180-2189 ◽  
Author(s):  
Mei jiang Feng ◽  
Ling Zhang ◽  
Zhengxia Liu ◽  
Ping Zhou ◽  
Xiang Lu
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
In Vitro Models

scholarly journals Grafts Derived from an α-Synuclein Triplication Patient Mediate Functional Recovery but Develop Disease-Associated Pathology in the 6-OHDA Model of Parkinson’s Disease

2020 ◽  
pp. 1-14
Author(s):  
Shelby Shrigley ◽  
Fredrik Nilsson ◽  
Bengt Mattsson ◽  
Alessandro Fiorenzano ◽  
Janitha Mudannayake ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cell Lines ◽  
Functional Recovery ◽  
Embryonic Stem ◽  
Hesc Line ◽  
Alternative Source ◽  
And Function

Background: Human induced pluripotent stem cells (hiPSCs) have been proposed as an alternative source for cell replacement therapy for Parkinson’s disease (PD) and they provide the option of using the patient’s own cells. A few studies have investigated transplantation of patient-derived dopaminergic (DA) neurons in preclinical models; however, little is known about the long-term integrity and function of grafts derived from patients with PD. Objective: To assess the viability and function of DA neuron grafts derived from a patient hiPSC line with an α-synuclein gene triplication (AST18), using a clinical grade human embryonic stem cell (hESC) line (RC17) as a reference control. Methods: Cells were differentiated into ventral mesencephalic (VM)-patterned DA progenitors using an established GMP protocol. The progenitors were then either terminally differentiated to mature DA neurons in vitro or transplanted into 6-hydroxydopamine (6-OHDA) lesioned rats and their survival, maturation, function, and propensity to develop α-synuclein related pathology, were assessed in vivo. Results: Both cell lines generated functional neurons with DA properties in vitro. AST18-derived VM progenitor cells survived transplantation and matured into neuron-rich grafts similar to the RC17 cells. After 24 weeks, both cell lines produced DA-rich grafts that mediated full functional recovery; however, pathological changes were only observed in grafts derived from the α-synuclein triplication patient line. Conclusion: This data shows proof-of-principle for survival and functional recovery with familial PD patient-derived cells in the 6-OHDA model of PD. However, signs of slowly developing pathology warrants further investigation before use of autologous grafts in patients.

Sign in / Sign up

Export Citation Format

Share Document